Trevena expects to receive a non-dilutive $2 million tranche and may be eligible for up to an additional $8 million based on OLINVYK US partnering and commercialization milestones

Trevena预计将获得200万美元的非稀释性部分，根据OLINVYK美国合作和商业化里程碑，Trevena可能有资格再获得800万美元

Trevena further expects a $10 million reduction in liabilities associated with its ex-US royalty financing

Trevena进一步预计，与美国特许权使用费融资相关的负债将减少1000万美元

CHESTERBROOK, Pa., July 08, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced an amendment (the “Amendment”) to its March 2022 ex-US royalty-based financing (the “Royalty Financing”) with R-Bridge Healthcare Fund, L.P.

宾夕法尼亚州切斯特布鲁克（CHESTERBROOK），2024年7月8日（环球通讯社）--Trevena，Inc.（纳斯达克：TRVN），一家专注于中枢神经系统（CNS）疾病患者新药开发和商业化的生物制药公司，今天宣布对其2022年3月与R-Bridge Healthcare Fund，L.P.的前美国专利权使用费融资（“专利权使用费融资”）进行修订（“修订”）。

(R-Bridge)..

（R桥）。

Pursuant to the Amendment, Trevena will receive (i) a $2 million payment from R-Bridge to Trevena, and (ii) $8 million in future potential tranches to Trevena based on the achievement of certain US partnering and commercial milestones for OLINVYK. In addition, the outstanding liability in connection with the Royalty Financing will be reduced by $10 million in connection with the Amendment.

根据该修正案，Trevena将收到（i）R-Bridge向Trevena支付的200万美元款项，以及（ii）根据OLINVYK在美国的某些合作和商业里程碑的成就，未来向Trevena支付800万美元的潜在份额。此外，与特许权使用费融资相关的未偿债务将因修订而减少1000万美元。

Trevena previously received $30 million in non-dilutive funding under the Royalty Financing..

Trevena之前在特许权使用费融资下获得了3000万美元的非稀释资金。

Also as part of the Amendment, (i) certain OLINVYK Chinese IP that had been previously pledged to R-Bridge under the Royalty Financing was transferred to R-Bridge, (ii) warrants that had been issued to R-Bridge as part of the Royalty Financing were amended to reduce the exercise price to a 15% premium to the current stock price and to extend the exercise period to five years from the date of the Amendment, and (iii) the existing cap on US royalty payable to R-Bridge was increased from $10 million to $12 million (with no minimum or fixed payments)..

作为修订的一部分，（i）之前根据特许权使用费融资向R-Bridge承诺的某些OLINVYK中国知识产权被转让给R-Bridge，（ii）作为特许权使用费融资的一部分向R-Bridge发行的认股权证被修订，以将行权价格降低至当前股价的15%溢价，并将行权期延长至自修订之日起的五年，（iii）应付给R-Bridge的美国特许权使用费的现有上限从1000万美元增加至1200万美元（无最低或固定付款）。

Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company’s strategy, future operations, clinical development and trials of its therapeutic candidates, plans for potential future product candidates and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “suggest,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995.

本新闻稿中关于公司未来预期、计划和前景的任何声明，包括关于公司战略、未来运营、临床开发和候选治疗药物试验的声明、潜在未来候选产品计划以及其他包含“预期”、“相信”、“估计”、“预期”、“打算”、“可能”、“计划”、“预测”、“项目”、“建议”、“目标”、“潜力”、“将”、“会”、“可能”、“应该”、“继续”等字样的声明，构成1995年《私人证券诉讼改革法》含义内的前瞻性声明。

Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the status, timing, costs, results and interpretation of the Company’s clinical trials or any future trials of any of the Company’s investigational drug candidates; the uncertainties inherent in conducting clinical trials; expectations for regulatory interactions, submissions and approvals, including the Company’s assessment of discussions with FDA; availability and adequacy of funding, including whether additional tranches of Royalty Financing will become available; uncertainties related to the Company’s intellectual property; other matters that could affect the availability or commercial potential of the Company’s therapeutic candidates and approved product; and other factors discussed in the Risk Factors set forth in the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission (SEC) and in other filings the Company makes with the SEC from time to time.

由于各种重要因素，实际结果可能与此类前瞻性声明所示的结果存在重大差异，包括：公司临床试验或公司任何研究候选药物的任何未来试验的状态，时间，成本，结果和解释；进行临床试验固有的不确定性；对监管互动、提交和批准的期望，包括公司对与FDA讨论的评估；资金的可用性和充足性，包括是否会提供额外的版税融资；与公司知识产权相关的不确定性；其他可能影响公司候选治疗药物和批准产品可用性或商业潜力的事项；以及公司向美国证券交易委员会（SEC）提交的10-K表年度报告、10-Q表季度报告以及公司不时向SEC提交的其他文件中规定的风险因素中讨论的其他因素。

About Trevena

关于Trevena

Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative medicines for patients with CNS disorders. The Company has one approved product in the United States, OLINVYK® (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate.

Trevena，Inc.是一家生物制药公司，专注于为中枢神经系统疾病患者开发和商业化创新药物。该公司在美国有一种经批准的产品OLINVYK®（oliceridine）注射液，适用于成年人，用于治疗严重到需要静脉注射阿片类镇痛药且替代治疗不足的急性疼痛。

CBC Group is Asia’s largest and most active healthcare-dedicated investment firm with over US$8.8 billion AUM. With a diversified, multi-product strategy, CBC Group is focused on platform-building, buyout, private credit and royalties, and real estate, across the healthcare space, including pharmaceutical, biotech, medical technology, and healthcare services.

CBC集团是亚洲最大、最活跃的医疗保健投资公司，拥有超过88亿美元的资产管理规模。CBC集团凭借多元化的多产品战略，专注于医疗保健领域的平台建设、收购、私人信贷和特许权使用费以及房地产，包括制药、生物技术、医疗技术和医疗保健服务。

CBC has a leading team of investment, industry and portfolio management professionals, headquartered in Singapore with additional offices in New York, Shanghai, Beijing, Hong Kong, London and Seoul..

CBC拥有一支由投资、行业和投资组合管理专业人士组成的领先团队，总部位于新加坡，在纽约、上海、北京、香港、伦敦和首尔设有办事处。

Founded in February 2020, R-Bridge Healthcare is an affiliate of CBC Group and it is dedicated in providing alternative, non-dilutive financing backed by royalties, revenue interest and other cash flows generated by the sale of healthcare products and services in Asia-Pacific region, the first of its kind for the asset class and the region.

R-Bridge Healthcare成立于2020年2月，是CBC集团的一家附属公司，致力于提供由特许权使用费、收入利息和亚太地区医疗产品和服务销售产生的其他现金流支持的替代性非稀释性融资，这是该资产类别和该地区首创的此类融资。

R-Bridge provides additional sources of capital to leading healthcare companies to continue their extraordinary growth trajectories, commercializing their products and services in Asia-Pacific region and on a global scale..

R-Bridge为领先的医疗保健公司提供了额外的资金来源，以继续其非凡的增长轨迹，在亚太地区和全球范围内将其产品和服务商业化。